Replies to post #60938 on GoodFellas Big Board Catalyst and Chart Plays

[$hylo]

INO..$.66. It has an impressive pipeline consisting of seven products in phase I or II and two in pre-clinical. These address prostate cancer, hepatitis C, HIV, influenza, malaria and tropical diseases. Importantly, its lead product, VGX-3100 for cervical cancer, will report out topline data from a phase II trial in 2H, 2013.

This year could be the coming out party for Inovio. Maxim Group starts at BUY.

http://seekingalpha.com/article/1124271-this-could-be-the-coming-out-year-for-inovio-pharmaceuticals?source=nasdaq

[deadjim]

As long as it holds intra support, might've found the low today. 4 down days + exhaustion gap.

gets shakey if it heads under 12.50 again